Study Looking at Safety of Dacomitinib and How it Works in the Body in People with Livers that Do Not Work Properly
A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Plasma Pharmacokinetics and Safety of Dacomitinib in Participants With Severely Impaired Hepatic Function Relative to Participants With Normal Hepatic Function
Category & Conditions: Cancer
Medicine: VIZIMPRO® TABLETS(DACOMITINIB)
ClinicalTrials.gov Identifier (NCT): NCT03865446
Protocol ID: A7471058
PrintDownloadOpen Plain Language Summary Result: Click here